C16orf73 Inhibitors
Chemical inhibitors of the protein encoded by the C16orf73 gene play a crucial role in dissecting the signaling pathways and cellular processes this protein is involved with. Wortmannin and LY294002, both phosphoinositide 3-kinases (PI3K) inhibitors, can disrupt the PI3K signaling cascade, leading to the downregulation of C16orf73 activity. This suggests that the protein's function is closely linked to the PI3K pathway. Similarly, the protein kinase C (PKC) inhibitor Go6976 can prevent necessary phosphorylation events, implying that C16orf73 activity requires PKC-mediated signaling. Furthermore, the TGF-beta receptor inhibitor SB431542 can inhibit C16orf73 by disrupting the TGF-beta-mediated signaling pathways, which could be key to the protein's function. PD173074, a specific inhibitor of the FGFR tyrosine kinase, and Lapatinib, an inhibitor of the EGFR and HER2 tyrosine kinases, can both impede the tyrosine kinase-dependent signaling events that are potentially crucial for C16orf73's functional role in cellular differentiation and proliferation.
The mTOR signaling pathway, targeted by Rapamycin, can affect various cellular processes that may involve C16orf73, indicating that the protein's activity could be intertwined with mTOR signaling. PD98059 and U0126, which are both MEK inhibitors, can obstruct the ERK signaling pathway, suggesting that C16orf73 may require ERK pathway activation for its activity. Bortezomib, by inhibiting the proteasome, can lead to the accumulation of misfolded proteins and disrupt cellular homeostasis, which can suggest that C16orf73 might be involved in proteostasis. Lastly, Dasatinib, a broad-spectrum tyrosine kinase inhibitor, can prevent the activation of tyrosine kinase-dependent pathways, which may be necessary for the activation and function of C16orf73, pointing to a potential regulatory relationship between these kinases and C16orf73 activity. Through the inhibition of these various pathways, researchers can elucidate the role of C16orf73 in cellular function and the signaling networks it is part of.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). Given that C16orf73 is involved in cellular processes regulated by PI3K signaling, wortmannin's inhibition of PI3K can lead to a decrease in the functional activity of C16orf73 by disrupting the signaling cascade necessary for its function. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol is known to inhibit the function of sigma receptors, which are implicated in intracellular signaling pathways. Inhibition of sigma receptors can disrupt pathways that may be crucial for the function of C16orf73, leading to its functional inhibition. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Go6976 is a potent protein kinase C (PKC) inhibitor. If C16orf73 is regulated by PKC-dependent signaling pathways, the inhibition of PKC by Go6976 could lead to the functional inhibition of C16orf73 by preventing its necessary phosphorylation events. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the TGF-beta receptor. TGF-beta signaling is involved in numerous cellular processes, including those that might engage C16orf73. Inhibition by SB431542 would disrupt TGF-beta-mediated signaling and could inhibit the functional activity of C16orf73. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is an inhibitor of the FGFR tyrosine kinase. Since FGFR signaling is involved in processes such as cell differentiation and proliferation, and these processes could entail the participation of C16orf73, inhibition by PD173074 would impair the functional activity of C16orf73. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is an inhibitor of the EGFR and HER2 tyrosine kinases. C16orf73 may have functional roles downstream of these receptors, and inhibition by Lapatinib would disrupt signal transduction pathways involving EGFR/HER2, leading to the functional inhibition of C16orf73. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, as mentioned earlier. It is included to emphasize its role in inhibiting PI3K-dependent pathways, which could be crucial for the functional activity of C16orf73. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and given that mTOR signaling affects various cellular processes, including those that could engage C16orf73, its inhibition would result in the functional inhibition of C16orf73 by disrupting necessary signaling events. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that would inhibit ERK pathway signaling. Since the ERK pathway is involved in a multitude of cellular functions, the inhibition by PD98059 could lead to the functional inhibition of C16orf73 by blocking necessary phosphorylation and activation steps. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor, which can lead to the accumulation of misfolded proteins and disrupt cellular homeostasis. If C16orf73 is involved in proteostasis, its functional activity could be inhibited by the action of Bortezomib. | ||||||